Molecular diagnostics company Myriad Genetics signed an agreement with PharmaMar, a company that specializes in developing marine-derived drugs, under which Myriad will conduct homologous ...

The TSO 500 HRD research test aligns Myriad’s gold standard MyChoice ® CDx HRD technology with Illumina’s pan-cancer test, TSO 500. The test was codeveloped with Merck (known as MSD outside the US and ...

SALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN) (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with GSK aimed at ...

Myriad Genetics, Inc. (NASDAQ: MYGN) today announced new clinical studies on its myChoice HRD companion diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in ...

FORT MYERS, Fla., June 30, 2025--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of ...

Myriad Genetics, Inc. MYGN recently announced a collaboration with GSK plc GSK to advance in the field of genetic testing. The latest development is intended to improve access to homologous ...

The filing comes as recent upgrades to NCCN guidelines expand the role of testing in the treatment of ovarian cancer. Myriad Genetics this week submitted the first part of its application to the FDA ...

Myriad Genetics, Inc. MYGN recently announced the expansion of a strategic partnership with Illumina Inc. ILMN to widen access to oncology homologous recombination deficiency (HRD) testing in the ...

Homologous recombination repair deficiency (HRD) is associated with response to poly-ADP-ribose polymerase inhibition (PARPi) therapy in advanced ovarian cancer. In combination with CGP, these ...

Tesaro has made a deal with Myriad Genetics to use Myriad's homologous recombination deficiency (HRD) test to look for tumor types that may respond to its poly-ADP ribose polymerase (PARP) inhibitor, ...

High grade serous ovarian cancer is characterized by genomic instability, with ~50% of advanced tumors harboring homologous recombination repair (HRR) pathway deficiency (HRD). HRD results in ...

A community-based study found that despite current guidelines recommending that all patients diagnosed with epithelial ovarian cancer undergo testing for homologous repair deficiency (HRD), only about ...